Navigation Links
Quanterix PSA Test Found to be a Reliable Predictor of Prostate Cancer Recurrence Following Surgery
Date:10/13/2011

CAMBRIDGE, Mass., Oct. 13, 2011 /PRNewswire/ -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA) technology, today announced results from a clinical evaluation of its Prostate Specific Antigen (PSA) test, a fifth-generation digital immunoassay, demonstrating that the assay is a reliable predictor of five-year biochemical recurrence (BCR)-free survival following radical prostatectomy (RP).  The pilot study was published online by the British Journal of Urology International.  

"These results have important implications for the way prostatectomy patients will be managed in the future," states Dr. Herbert Lepor, prostate cancer expert and Chairman of the Department of Urology at NYU School of Medicine.  "Not only will physicians be able to reassure patients who are at low risk of recurrence following radical prostatectomy, but the identification of a reliable predictor of recurrence soon after surgery has important implications for the frequency of PSA testing and selection of candidates for adjuvant therapy.  In addition to providing patients with peace of mind, implementation of this test could lead to a reduction in healthcare costs."  

To determine the ability of this test to predict five-year BCR-free survival following RP, researchers utilized frozen serum specimens, provided by NYU Langone Medical Center and the Johns Hopkins University School of Medicine, from men who had undergone RP and who had no evidence of BCR using conventional PSA measurement methods.  The Quanterix single molecule PSA assay, which has an analytical sensitivity 1000-fold lower than conventional ultrasensitive PSA assays, was capable of accurately measuring PSA levels in all men following surgery.   Researchers found that the PSA nadir value (lowest level of PSA following RP) was a significant predictor of BCR.  A Kaplan Meir analysis demonstrated that 100% of men with low PSA nadir values did not develop BCR, whereas 63% of men with higher PSA values eventually recurred.  The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the SiMoA PSA test was 100%, 75%, 69% and 100% respectively.  

"We are encouraged by these results, which further supports the value of our SiMoA platform," said Martin Madaus, Ph.D., Executive Chairman of Quanterix.  "We are actively validating assays important in oncology and several other applications while working towards our goal of automating the SiMoA system to offer a menu of assays to the life sciences and in vitro diagnostics markets."

Data from this pilot study was also presented at the American Association of Clinical Chemistry in July and focused on the analytical performance of the PSA test, which demonstrated improved sensitivity over current PSA assays.  

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.


'/>"/>
SOURCE Quanterix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Quanterix Digital ELISA Measures Low Abundance Biomarkers of Inflammation in Crohns Disease
2. Quanterix and STRATEC Announce Strategic Partnership
3. Quanterix Announces Publication of Novel Method Expanding Single Molecule Detection Capability
4. Quanterix Announces New Technology Evaluation Agreement
5. Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
6. Pandora Founder Tim Westergren and Co-Discoverer of DNA Dr. James Watson Meet
7. Health fears over CO2 storage are unfounded, study shows
8. Major grant from the National Science Foundation will sustain UCSB materials research through 2017
9. Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy
10. Society of Interventional Radiology Foundation Funds Howard Hughes Medical Institute Award
11. Society of Interventional Radiology Foundation Welcomes Corporate Gift From Sirtex Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
(Date:6/22/2016)... Research and Markets has announced the addition ... their offering. The global ... billion in 2013. The market is expected to grow at a ... 2020, increasing from $50.6 billion in 2015 to $96.6 billion in ... forecast period (2015 to 2020) are discussed. As well, new products ...
Breaking Biology Technology:
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
(Date:6/9/2016)... 9, 2016 Paris Police ... video security solution to ensure the safety of people and ... during the major tournament Teleste, an international technology ... services, announced today that its video security solution will be ... back up public safety across the country. The system roll-out ...
Breaking Biology News(10 mins):